Table 1. AA administration prevented cardiac dysfunction in the pressure-overloaded hearts.
| Parameter | Sham | Sham + AA | TAC | TAC + Vehicle | TAC + AA |
|---|---|---|---|---|---|
| IVSD, mm | 0.741±0.059 | 0.753±0.101 | 1.106±0.106*** | 1.073±0.094*** | 0.860±0.125### |
| IVSS, mm | 1.093±0.125 | 1.167±0.085 | 1.399±0.093*** | 1.366±0.052*** | 1.163±0.176## |
| LVEDD, mm | 3.304±0.149 | 3.323±0.192 | 3.098±0.174* | 3.101±0.142* | 3.372±0.258# |
| LVESD, mm | 1.963±0.134 | 1.983±0.100 | 2.103±0.198 | 2.049±0.060 | 2.096±0.146 |
| LVPWD, mm | 0.742±0.107 | 0.774±0.078 | 1.259±0.138*** | 1.237±0.130*** | 0.840±0.167### |
| LVPWS, mm | 1.451±0.165 | 1.428±0.108 | 1.458±0.089 | 1.463±0.073 | 1.310±0.076## |
| %EF | 77.720±3.551 | 74.350±4.337 | 62.800±2.917*** | 60.120±8.178*** | 70.570±6.638# |
| %FS | 40.630±1.881 | 40.300±1.051 | 31.590±3.011*** | 32.900±1.485*** | 37.760±2.231## |
| LV mass, mg | 96.020±9.176 | 98.330±4.313 | 122.400±9.334*** | 123.940±14.080*** | 98.600±18.340## |
Mice were orally gavaged with AA 100 mg/kg/day or the vehicle for 2 weeks after TAC. All values are mean ± standard deviation (SD). n=10 mice/group. *P<0.05 and ***P<0.001 vs. sham group; #P<0.05, ##P<0.01, and ###P<0.001 vs. TAC group. AA, asiatic acid; TAC, transverse aortic constriction; IVSD, interventricular septum diastolic dimension; IVSS, interventricular septum systolic dimension; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVPWD, left ventricular posterior wall thickness diastole; LVPWS, left ventricular posterior wall thickness systole; EF, ejection fraction; FS, fractional shortening; LV, left ventricle.